VigiLanz Launches COVID Quick Start, a Respiratory Viral Illness Prevention Software, Partnering with Datica for Rapid Deployment

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months

MINNEAPOLIS – May 20, 2020 – VigiLanz, a clinical surveillance company, today announced COVID Quick Start – a new solution that will enable hospitals to prepare for, prevent, and respond to the spread of COVID-19 and other respiratory viral illnesses. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Partnering with Datica for rapid deployment and supported by a team of VigiLanz’s certified infection preventionists, the software is designed to alleviate the burden on hospital IT resources and clinical staff while increasing patient safety. The solution is available for free for the first six months, with flexible financing options thereafter.

Learn more

COVID Quick Start uses VigiLanz’s clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. The platform continuously pulls patient data from a variety of sources, including EHRs, and evaluates that data against rules that issue real-time alerts to clinical staff. The rules are designed to identify potential respiratory viral illnesses, ensuring early isolation and management of patients, and can also track disease clusters to identify local outbreaks and hospital acquisition.

“Our team recognized that VigiLanz’s software and expertise could be tailored to address the unique issues presented by this pandemic and other potential respiratory viral illnesses, and that we could design a solution with a low barrier to entry,” said Stacy Pur, Vice President of Product Development at VigiLanz. “We’ve built COVID Quick Start as a solution that works both for hospitals with well-funded infection prevention programs, and those where resources may be more restricted. These organizations are facing a possible second wave of COVID-19 on top of the upcoming influenza season. Our Quick Start solution, which provides the basics of what hospitals need to monitor – such as exposures, early case identification, COVID-19 state and federal reporting requirements, and isolation – will help hospitals quickly prepare for what is coming.”

Recognizing the urgency for hospitals to have a solution like this in place, COVID Quick Start uses VigiLanz Connect, an API solution for hospital EHRs, powered by Datica, to deliver an even faster integration. This solution minimizes the burden on hospital IT resources and enables COVID Quick Start to begin improving patient safety as quickly as possible.

“Datica has deep expertise, with over 400 successful EHR integrations,” said Dave Levin, MD, Chief Medical Officer at Datica. “We’re proud to collaborate with VigiLanz as their EHR integration partner to quickly launch their COVID Quick Start product.”

COVID Quick Start provides an easy and low-risk entry to the full suite of VigiLanz’s SaaS-based clinical surveillance solutions. VigiLanz helps health systems avoid or minimize harm, optimize clinical outcomes, and support preventive care by aggregating and monitoring disparate data in real time from across the EHR and other health system databases. VigiLanz was ranked No. 1 by KLAS Research this year across three categories – Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the third year in a row it has earned Category Leader designations from KLAS.

Learn more about COVID Quick Start at vigilanzcorp.com/covid-19/.

 

###

 

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

About Datica

Datica is the only managed service provider (MSP) that solves healthcare’s biggest roadblocks–EHR integration and cloud compliance. Its integration solution enables data integration from any source, to any destination, in any format – without sacrificing PHI security. Datica’s cloud compliance solution offers end-to-end managed services for digital innovators to scale rapidly in the cloud, while ensuring HIPAA compliance and HITRUST certification are in place.

With over 400 live integrations and compliant cloud infrastructure for Fortune 500 companies, Datica’s deep expertise gives you the confidence and infrastructure to scale quickly and securely. For more info, visit: https://datica.com.

 

My Favorite VigiLanz Rule: Pharmacists and IPs Share Their Top Picks

At VigiLanz, data rules! And as a VigiLanz customer, you can create more actionable data by tapping into our extensive rules library or creating new rules based on your unique needs. Our clinical experts are always standing by to help, whether you need help adjusting an existing rule or creating something new.

We’ve gathered some inspiration from real VigiLanz customers on their favorite and unique VigiLanz rules that have a significant impact on patient care.

 


Biofire Alert

Jeremy Frens, PharmD, BCPS-AQID, Antibiotic Stewardship Coordinator at Cone Health

“My favorite rule is the positive Biofire alert. We have customized the alert so that our antimicrobial stewardship team and ID physicians get email or text alerts based on the organism detected. Our hospital has a policy that an ID physician sees patients with Staph aureus, Candida, or enterococcal bacteremia. With the text or email alerts going directly to them, they can respond quickly, often the same day as the alert. We feel that this process helps to streamline antibiotics more quickly!”


High Risk C. difficile

Erica Lawrence, MSN, RN, Infection Preventionist at Virginia Mason Medical Center

“My favorite one is the high risk C. difficile rule. This rule helps to alert us proactively of patients at risk for C. difficile, but not necessarily diagnosed or symptomatic with C. diff. This allows for the AMS group to review prescribed medications and make recommendations to the providers if de-escalation of antibiotics or gastric acid suppressors is appropriate. Another intervention is adding signs and symptoms of C. difficile to the discharge instructions to ensure patients are educated about when to follow up with their provider if signs and symptoms of C. difficile begin after discharge.”


Critical Medication Discontinued

Jill Bennett, PharmD, APh, BCPS, Clinical Pharmacy Coordinator at Antelope Valley Hospital

“Some of my favorite rules are the ones that alert us to medications that have been discontinued when that might be detrimental to a patient outcome. For example: Levetiracetam DC’d and no active anticonvulsant order, or in patients with prolonged LOS when routine medications may fall off the profile from an ASO: Inpatient Day #30 – Check Med Profile. The real-time culture info is also nice.”


Patient Discharge SNF

Chrissie Wiebe, Infection Preventionist at Maury Regional Medical Center

“I would have to say my favorite rule we have is the “Pt Discharge SNF (CMP-QI Grant Locations)”. I like this rule because we are able to track patients who are going to certain nursing homes at discharge using keywords in their documentation. This rule is helpful because we have a grant that is allowing us to work with certain local nursing homes to help prevent readmission. This rule allows us to know which patients are going to these locations so we can get a better idea as to where our patients are going and how we can best serve the SNF’s in order to prevent a possible readmission for something they can take care of at their facility.”


Highly Infectious Disease Email Alerts

Jordan Ehni, CIC, MPH, Systems Integration Infection Preventionist at Mount Sinai Health System

“I think my favorite rule/function are the email alerts that we can set up for when a patient with a highly infectious disease comes into the hospital. We don’t have time to constantly check VigiLanz throughout the workday, so it is good to know we have this ‘back up’ alert if we go a few hours between checking our Isolation Bucket.”


Highly Infectious Disease Email Alerts

Sarah Lowtharp, MSN, RN, CIC, Assistant Director of Infection Prevention at St. Bernards Medical Center

“My favorite rules are centered on alerting us of highly infectious patients immediately. I get an email alert from a rule trigger in VigiLanz on possible meningitis, possible TB, CROs, and possible Candida auris (the Candida isolates we are required to send to dept. of health for auris testing). I usually receive my email/VigiLanz alert before our own lab notifies us of these scenarios.”

 


Real-Time Blood Culture Contamination Results

Frank Vanskike, MPH, CIC, Infection Preventionist at Phoenix Children’s

“We worked with our VigiLanz team to build a rule around blood culture contamination results in our ED. These reports alerted us in real-time as opposed to the previous method where we were provided the contamination rate at the end of the month. We were able to build a report off of the rule and disseminate to the ED and stakeholders on a weekly basis. This intervention helped us track when and where contamination on blood draws were occurring so real-time education and feedback could be provided. Furthermore, this helped the ED because the report enabled us to communicate to the ED patients that had contaminated specimens that were not true infections and did not need to return to the ED to seek treatment. This saved a return visit to the hospital for families, avoided potential readmissions, prevented unnecessary antibiotic use, and eliminated unnecessary financial costs.”

 


Metabolic Support Consult for ICU & Ventilator Patients

Adrienne Carey, PharmD, BCPS, Clinical Pharmacist / Data Mining Program Manager at Freeman

“We created a group of rules to alert our Metabolic Support Team to the fact that a patient in our ICU is on a ventilator and may need a metabolic support consult for enteral or parenteral nutrition management. A metabolic support consult can sometimes get overlooked in these patients since at the time of admission they do not have an immediate need for nutritional support and no order for such is entered by a physician, but these patients still need to be monitored closely as after a period of time on sedation, they will need nutritional support. Our Metabolic Support Team is alerted to about 30 patients per month with these rules.”

Safety Is a Top Priority for Hospitals, Yet Many Report Safety Gaps

By Stacy Pur, Vice President of Product Development at VigiLanz

Safety is a top priority for hospital leaders, yet many feel that their organization could make significant safety improvements. That’s according to a survey of 123 hospital chief medical officers, chief nursing officers, chief quality officers, and other C-suite leaders conducted by Sage Growth Partners, a healthcare consulting firm.

You can read more of this article on Patient Safety & Quality Healthcare.  

For more on how VigiLanz can improve patient safety, click here.

VigiLanz Recognized for High Customer Retention, Innovation in KLAS 2019 Infection Control Report

MINNEAPOLIS – March 14, 2019 – VigiLanz, a clinical surveillance company, has been featured in the Infection Control 2019 Report from KLAS Research, released today. The report aggregates and analyzes interviews from thousands of healthcare professionals about the products and services their organizations use.

In the report, KLAS characterizes VigiLanz as a market leader for its high customer retention and innovative technology additions, such as active alerting, in its Dynamic Infection Control Monitor product. VigiLanz is also recognized for providing advanced automation and predictive analytics, two capabilities KLAS identified as highly desired by the market.

“Before we had [VigiLanz’s] Dynamic Infection Control Monitor, I did everything with manual data extraction,” said one anonymized user in the report. “I would have to run about 12 different reports to even get a list of patients to perform surveillance on, and I would need another six reports to get all the communicable disease reporting. [The] Dynamic Infection Control Monitor has made my job so much easier. It is a lot more efficient. I can easily get my patient list and go through it.”

Another anonymized user said, “We consider VigiLanz to be the leader in surveillance because of the flexibility of what we can do with the surveillance.”

VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with EMR systems. Its automatic exception-based alert system continuously surveils all patient records to alert decision makers in real time of potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“We understand how critical an infection prevention product is for patient outcomes and hospitals’ bottom lines, and we’re dedicated to the ongoing innovation that ensures we continue delivering what patients and the market needs,” said David Goldsteen, MD, CEO of VigiLanz. “In general, healthcare executives say infection prevention is one of the top five uses of clinical surveillance technology,[1] and it has rapidly become a critical component of quality patient care.”

The other top uses of clinical surveillance technology, according to healthcare executives, are:

1) Identifying adverse drug events
2) Promoting antimicrobial stewardship
3) Patient safety alerting
4) Managing readmissions

In addition to being a leader in this report, KLAS recognized VigiLanz in the 2019 Best in KLAS report, earning 2019 Category Leader designations for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EMR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

[1] Market Report: Clinical Surveillance: The Next Step in Value-Based Care. Feb. 2019. VigiLanz.

IllumiCare and VigiLanz Partner to Help Pharmacists and Clinicians Advance Antimicrobial Stewardship

Houston Methodist Sugar Land Hospital first in country to launch new point-of-care alert solution with pharmacist-only rollout.

BIRMINGHAM, HOUSTON, & MINNEAPOLIS – February 6, 2018 – The CDC estimates that 20 to 50 percent of antibiotics prescribed in U.S. acute-care hospitals are unnecessary or inappropriate. With the need for healthcare systems and federal agencies to increase their focus on antibiotic stewardship, both providers and pharmacists play a vital role in monitoring safe and appropriate use. Today, VigiLanz, a clinical surveillance company, and IllumiCare, a leading provider of point-of-care technology, announce a partnership to increase visibility within providers’ and pharmacists’ normal workflows around antimicrobial therapy monitoring.

IllumiCare’s Smart Ribbon® is an EMR-agnostic, non-intrusive ribbon of information that hovers over the EMR and provides patient-specific information such as the costs and risks of medications and tests, opioid exposures, and more. The Smart Ribbon displays VigiLanz’s Antimicrobial Stewardship Solution in a more visible, convenient and accessible place in the EMR when the provider or pharmacist is making care decisions. With this ability to respond to context in real-time, the Smart Ribbon only delivers notifications on issues or opportunities that busy clinicians and pharmacists can personally act on. This increases engagement with the VigiLanz insights and saves pharmacists the time and energy often spent tracking down a clinical counterpart to resolve an activation that’s halting the workflow.

“One key element to promoting antimicrobial stewardship is making sure the information is easily accessible to the right clinician or pharmacist when they need it most,” said GT LaBorde, CEO of IllumiCare. “VigiLanz provides real-time information related to safe antibiotic use that can reduce overprescribing or inappropriate prescribing and ultimately, lower costs. By making this information not only easier to see and more actionable, but also appropriately tailored to the person taking the action, antimicrobial stewardship efforts will be more successful.”

Houston Methodist Sugar Land Hospital is the first health system to deploy the VigiLanz clinical surveillance alerts within IllumiCare’s Smart Ribbon. Pharmacists can choose to engage with VigiLanz activations by viewing them, marking them as necessary and providing comments, all within their current workflow in the EMR. One of the most important activations is the visibility of drug-bug mismatches, in which the antimicrobial a patient receives is not adequate for the microbiological organism presumed to be causing the clinical infection. Additionally, the VigiLanz alerts highlight broad antimicrobial use, de-escalation opportunities, and conversion opportunities to move the patient to an antibiotic that has equal efficacy but is less expensive, such as from IV drugs to oral medications.

“Having actionable insights into antimicrobial use is critical; being able to put those insights in front of clinicians and pharmacists at the point of care is industry-leading,” said David Goldsteen, MD, CEO of VigiLanz. “We’re thrilled to be partnering with IllumiCare to deliver our trusted clinical surveillance insights through their Smart Ribbon to those who take action, ensuring safe and appropriate antimicrobial use.”

For more information, visit Illumicare at www.illumicare.com and VigiLanz at www.vigilanzcorp.com

VigiLanz Ranked No. 1 by KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance

MINNEAPOLIS – Jan. 31, 2019 – VigiLanz, a clinical surveillance company, today announced that it has earned 2019 Category Leader designations from KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance.

This is the second year VigiLanz has earned the No. 1 distinction for multiple categories. The company previously achieved Category Leader status in 2018 for Infection Control and Monitoring and Pharmacy Surveillance. Antimicrobial Stewardship is a new KLAS category for 2019.

Three VigiLanz products were recognized in the “2019 Best in KLAS: Software and Services” report, released on January 31:

VigiLanz Dynamic Infection Control Monitor

Earning a score of 90.6, the Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Its automatic exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

VigiLanz Dynamic PharmacoVigilance

Earning a score of 93.0, Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

VigiLanz Antimicrobial Stewardship

Earning a score of 94.6, the Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and provides direct reporting to the Centers for Disease Control’s National Healthcare Safety Network.

“It’s an honor to be recognized by KLAS as a leader in multiple categories for the second time, validating the confidence and trust we know our customers have in our clinical surveillance products,” said VigiLanz Chairman and CEO David Goldsteen, MD. “KLAS’ global reputation for accurately and impartially measuring vendor performance is an unparalleled channel for customer feedback – something we find invaluable to our culture of continued innovation. We look forward to continuing to provide industry-leading solutions to hospitals across the country that improve the safety and quality of patient outcomes.”

The KLAS Category Leader designation is awarded to vendors that lead select market segments in which at least two products meet a minimum number of KLAS Konfidence reviews. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

VigiLanz and Cincinnati Children’s Collaborate to Commercialize a Real-Time Solution to Minimize Acute Kidney Injury in Pediatrics

MINNEAPOLIS & CINCINNATI – (November 29, 2018) – VigiLanz and Cincinnati Children’s Hospital Medical Center today announced a collaboration that leverages Cincinnati Children’s ground-breaking research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for Acute Kidney Injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Dr. Stuart L. Goldstein, MD, FAAP, FNKF, Director of the Center for Acute Care Nephrology and primary researcher on NINJA.  “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially-available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates a time-consuming manual screening process that includes evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye, and recent renal testing. For medications, manual screening is limited to the last 24 hours, while the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data, and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

“By expanding awareness of the extensive research conducted by Cincinnati Children’s, this partnership will help drive improvements in pediatric AKI outcomes,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Those improvements can be realized quickly, too, as the NINJA dashboard is not just a concept but rather a tangible solution now available to any hospital interested in limiting AKI associated with nephrotoxic drugs.”

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

Interoperability in Real Life: Practical Ways to Leverage APIs & Transform Healthcare

Interoperability between EMRs and other applications is a key challenge in healthcare today. Application Programming Interfaces (APIs) have transformed interoperability in other industries and now healthcare, too, is increasingly relying on them to solve important clinical and business problems. VigiLanz recently co-hosted a panel discussion on the topic, with one of its partners, Sansoro Health, which featured leaders from a diverse group of healthcare organizations, who shared how they use proven API solutions to successfully address complex, real-world clinical, operational and workflow challenges.

Although the three panelists were at different stages of their journey in leveraging APIs to provide better healthcare solutions, more rapidly and at lower cost, all recognize that legacy technology does not meet their needs for integration with EMRs and data liquidity.

The Longest-Established API User

As moderator of the panel discussion, David Levin, MD, Chief Medical Officer of Sansoro Health and former CMIO of Cleveland Clinic Health System, explained it’s vital to have bi-directional data flow back into EMRs to save clinicians from double documenting. It’s an issue that Peter Chang, MD, Chief Medical Information Officer, Tampa General Hospital, faced, until he implemented Sansoro Health’s Emissary® API solution to deliver efficient, real-time read-and-write EMR interaction across complete patient demographics and clinical data. The longest established API user of the group, Dr. Chang spoke about how his hospital leverages APIs to focus solely on their application and not get disrupted on the integration. Tampa General Hospital can now integrate in a matter of days across EMRs, sourcing all the data its clinicians need.

The Middle Stage of the Middleware Journey

Adam Klass, Chief Technology Officer of VigiLanz, at the middle stage of the middleware journey, spoke on how APIs reduce barriers to EMR integration and can be rapidly deployed to provide robust, real-time interoperability between complex applications. To help healthcare providers deliver real-time results and  improve interoperability, he described how medical facilities today require a services-oriented architecture and API. The API must enable efficient aggregation, interaction and exchange of disparate data throughout the health care enterprise and across any of its software technologies, including EMRs and third-party vendors.

Klass, one of the company’s original founders in 2001, outlined the company’s mission of providing real-time clinical decision support to its customers by helping with all manners of manual data collection processes, using data and real-time rules engines. From pharmacy surveillance and predictive models to antimicrobial stewardship and other clinical use cases, the company relies on receiving EMR data in a timely manner. VigiLanz has always sought to answer the question of how to extract data from an EMR. It wasn’t rocket science, in Klass’ words, and yet it was challenging to collect the same data from every hospital in every EMR, in a way that enabled customers to have an intimate understanding of provider behavior through benchmarking. A creative solution was needed.

It’s one reason VigiLanz partnered with Sansoro Health to develop its VigiLanz Connect solution, which plugs into an organization’s EMR in less than one week for hospital IT-lite integration. Traditional integration methods are often customized for each installation, require regular maintenance and cannot be reused. Using a standard set of population-based APIs that facilitate seamless, real-time, bi-directional data flow, VigiLanz Connect normalizes data faster—and empowers clinicians to make an impact sooner. It plugs in once to deliver standardized, interchangeable APIs for seamless integration across all data sources. VigiLanz Connect has now been successfully deployed at several hospitals.

Exploring the Advantages to APIs

Matthew Cunningham, Executive Vice President of eviCore, described how his company is comprised of more than one thousand doctors and nurses in its ranks, so it needs a robust, flexible platform to identify and distribute the precise data and analytics to make informed, individual-based decisions across the 100 million lives it manages. With an understanding for the types of clinical and business problems that can be addressed with API technology, eviCore has begun to explore the advantages of commercially available APIs, like Sansoro Health’s Emissary platform.

Plug-and-play EMR integration is a reality today. Within days, hospital organizations are up and running with a standard set of APIs that work the same across EMRs. By leveraging middleware, organizations only code their application once for seamless integration across all data sources. This eliminates the need to build traditional custom interfaces for each EMR, saving significant time, resources and reducing costs – for clinicians, the hospital IT department and third-party solutions.

Connexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient Safety

BOULDER, CO & TORONTO, ON – (February 28, 2018) – Connexall and VigiLanz, both named Category Leaders in the 2018 Best in KLAS awards, have teamed up to deliver time-sensitive information related to antimicrobial stewardship (AMS) to increase patient safety and improve outcomes at hospitals.

The VigiLanz AMS platform aggregates information from physician order entries, laboratory and pathology reports, and the EHR to provide continuous surveillance of patients.  Connexall integrates with VigiLanz and the EHR to intelligently route data quickly and reliably to the assigned care team for the affected patient. This guides the care team to ensure safe and appropriate use of antibiotics.

“AMS has emerged as a central component of highly effective care quality and safety strategies, and success requires the ability to rapidly transform data into action,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “This partnership between VigiLanz and Connexall does just that, providing our customers with a robust AMS solution that leverages the power of two KLAS category leaders to drive improved patient outcomes.”

“Connexall is delighted to partner with VigiLanz to enhance antimicrobial stewardship programs for the benefit of patients.” stated David Tavares, GlobeStar/Connexall CEO.  “Our intelligent routing capabilities ensure that the assigned care team is notified promptly and reliably to deliver the care the patients require.” continued Tavares.

To learn more about this progressive solution, please visit VigiLanz at Booth #2674 and Connexall at Booth #8105 at HIMSS18.

About Connexall

Connexall, ranked number one and named Category Leader in the 2015/2016, 2017, and 2018 Best in KLAS awards, is an enterprise-grade event management and control platform that delivers hospital-wide interoperability to people, systems, tasks, and devices.  Its capabilities act as a backbone for clinical workflow, communicating the right information to the right person, at the right time, on the right device. Based on more than 20 years of R&D efforts, the Class II medical device software is completely vendor-neutral and device-independent. Connexall has offices in Canada, the United States, Brazil, Portugal and Hong Kong and works with well over a thousand of the world’s most renowned and progressive hospitals and health systems.  For more information please visit www.connexall.com.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

VigiLanz Ranked #1 in Best in KLAS Report for Infection Control and Clinical Decision Support-Surveillance Categories

MINNEAPOLIS – (January 31, 2018) – VigiLanz, a digital healthcare intelligence firm, announced today that it has earned 2018 Category Leader designations for Infection Control and Clinical Decision Support-Surveillance in the 2018 Best in KLAS: Software and Services report. These mark the second and third KLAS honors in the past year for VigiLanz, which also achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report for its platform, customer partnerships, and dedication to customer service and support.

In the “2018 Best in KLAS: Software and Services,” report, released on January 30, VigiLanz’s Dynamic Infection Control Monitor  product garnered a score of 90.3 while its Dynamic PharmacoVigilance product earned an 89.9.

The Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence. Rankings are based on customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment solutions.

Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Via an automatic exception-based alert system, all patient records are under continuous surveillance to alert decision makers in real time to potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of rule engines that can be customized for each hospital.

Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, the system automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“VigiLanz is honored to see our solutions recognized as Category Leaders, particularly as healthcare professionals are the engine that drives KLAS’ impartial research on the software and services used by providers worldwide,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Following upon VigiLanz’ recognition by KLAS in 2017 for our Antimicrobial Stewardship products, these additional designations further validate our reputation among clinicians and administrators alike as a company that offers the best, top-performing solutions in the industry.”

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.